Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic.

2020-08-01

Segelov, Eva

Underhill, Craig

Prenen, Hans

Karapetis, Christos

Jackson, Christopher

Nott, Louise

Clay, Tim

Pavlakis, Nick

Sabesan, Sabe

Heywood, Ellen

Steer, Christopher

Lethborg, Carrie

Gan, Hui K

Yip, Desmond

Karanth, Narayan

Karikios, Deme

MacIntyre, C Raina

Department of Oncology, Monash University and Monash Health, Melbourne, Victoria, Australia.

Border Medical Oncology, Albury-Wodonga Regional Cancer Centre, and University of NSW Rural Clinical School, Albury Campus, Albury, New South Wales, Australia.

Department of Oncology, University Hospital Antwerp, Edegem, Belgium.

Department of Medical Oncology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.

Department of Medicine, University of Otago, Dunedin, New Zealand.

Department of Medical Oncology, Royal Hobart Hospital, Hobart, Tasmania, Australia.

Department of Oncology, St John of God Subiaco Hospital and School of Medicine and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.

Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Department of Medical Oncology, Townsville Cancer Centre, Townsville Hospital and Health Services, Townsville, Queensland, Australia.

Cancer Services, Monash Health, Melbourne, Victoria, Australia.

Border Medical Oncology, Albury-Wodonga Regional Cancer Centre, and University of NSW Rural Clinical School, Albury Campus, Albury, New South Wales, Australia.

Inclusive Health Research, St Vincent's Health Australia, Melbourne, Victoria, Australia.

Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Victoria, Australia.

La Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australia.

Department of Medicine, University of Melbourne, Heidelberg, Victoria, Australia.

Department of Medical Oncology, The Canberra Hospital and ANU Medical School, Australian National University, Canberra, Australian Capital Territory, Australia.

Department of Medicine, Royal Darwin Hospital, Darwin, Northern Territory, Australia.

Department of Medical Oncology, Nepean Hospital and Nepean Clinical School, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Biosecurity Program, Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.

Betacoronavirus

COVID-19

Coronavirus Infections

Delivery of Health Care

Humans

Medical Oncology

Neoplasms

Pandemics

Pneumonia, Viral

Risk Factors

SARS-CoV-2

Telemedicine

Journal Article

Publication

Cancer has become a prevalent disease, affecting millions of new patients globally each year. The COVID-19 pandemic is having far-reaching impacts around the world, causing substantial disruptions to health and health care systems that are likely to last for a prolonged period. Early data have suggested that having cancer is a significant risk factor for mortality from severe COVID-19. A diverse group of medical oncologists met to formulate detailed practical advice on systemic anticancer treatments during this crisis. In the context of broad principles, issues including risks of treatment, principles of prioritizing resources, treatment of elderly patients, and psychosocial impact are discussed. Detailed treatment advice and options are given at a tumor stream level. We must maintain care for patients with cancer as best we can and recognize that COVID-19 poses a significant competing risk for death that changes conventional treatment paradigms.

link

JCO Oncol Pract . 2020 Aug;16(8):467-482. doi: 10.1200/OP.20.00229. Epub 2020 May 13.

2688-1535

https://pubmed.ncbi.nlm.nih.gov/32401686/?otool=iaurydwlib